Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer

Oncologist

Volumn 18, Issue 12, 2013, Pages 1262-1269

  Owonikoko, Taofeek K ^a,b   Chowdry, Rajasree P ^a   Chen, Zhengjia ^b,c   Kim, Sungjin ^b   Saba, Nabil F ^a,b   Shin, Dong M ^a,b   Khuri, Fadlo R ^a,b  

^a UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Biologic agents; Second line; Thyroid cancer

Indexed keywords

BORTEZOMIB; EVEROLIMUS; LENALIDOMIDE; OCTREOTIDE; PASIREOTIDE; SORAFENIB; SUNITINIB; VANDETANIB;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GENDER; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE TIME; RETROSPECTIVE STUDY; SURVIVAL RATE; THERAPY EFFECT; THYROID CANCER; TREATMENT FAILURE; TUMOR VASCULARIZATION;

BIOLOGIC AGENTS; SECOND-LINE; THYROID CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERIDINES; QUINAZOLINES; RETROSPECTIVE STUDIES; SIROLIMUS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84890050249     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0250     Document Type: Article

References (29)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-2167.
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the united states, 1988-2005. Cancer 2009;115:3801-3807.
3. Palme CE, Waseem Z, Raza SN et al. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:819-824.
4. Tsang RW, Brierley JD, Simpson WJ et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82: 375-388.
5. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-2516.
6. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011;12:1004-1012.
7. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529.
8. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
9. Bible KC, Suman VJ, Molina JR et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010; 11:962-972.
10. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
11. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684.
12. Wells SA, Gosnell JE, Gagel RF et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-772.
13. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.
14. Wells SA, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012;30: 134-141.
15. Kurzrock R, Sherman SI, Ball DW et al. Activity of XLl184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-2666.
16. Cabanillas ME, Hu MI, Durand JB et al. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res;2011:985780.
17. Brose MS, Nutting CM, Sherman SI et al. Rationale and design of decision: A double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349.
18. Harvey RD, Kauh JS, Ramalingam SS et al. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. J Clin Oncol 2010;28:5589a.
19. Owonikoko TK, Harvey RD, Kauh JS et al. A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. J Clin Oncol 2012;30:2576a.
20. Thornton K, Kim G, Maher VE et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary Clin Cancer Res 2012;18:3722-3730.
21. Brose MS, Nutting C, Jarzab B et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III decision trial. J Clin Oncol 2013; 31:4a.
22. Porta C, Procopio G, Carteni G et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): An Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011;108: E250-E257.
23. Dudek AZ, Zolnierek J, Dham A et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61-67.
24. Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: A retrospective outcome analysis. Eur Urol 2008;54: 1373-1378.
25. de la Fouchardiere C, Massicotte M-H, Borget I et al. Sequential TKI treatments for iodine-refractory differentiated thyroid carcinomas. J Clin Oncol 2013;31:6092.
26. Jain L, Woo S, Gardner ER et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 2011;72: 294-305.
27. Lupi C, Giannini R, Ugolini C et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92: 4085-4090.
28. Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-3949.
29. Kim TY, Kim WB, Rhee YS et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65: 364-368.